EGFR and neoplasm: For patients with Cluster #3 tumours, selected epigenetic drugs or EGFR/FGFR inhibitors may represent attractive treatment options.<h4>Conclusions</h4>Our novel molecular taxonomy holds promise as a practical framework for patient risk stratification and clinical trials in UC.